PBYI - Puma Biotechnology Inc Stock Price, Fair Value and News

$2.75-0.03 (-1.08%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PBYI Price Action

Last 7 days

-4.5%

Last 30 days

-3.2%

Last 90 days

5.8%

Trailing 12 Months

-30.2%

PBYI RSI Chart

PBYI Valuation

Market Cap

135.0M

Price/Earnings (Trailing)

5.81

Price/Sales (Trailing)

0.55

EV/EBITDA

2.06

Price/Free Cashflow

4.45

PBYI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PBYI Fundamentals

PBYI Revenue

Revenue (TTM)

243.6M

Rev. Growth (Yr)

43.53%

Rev. Growth (Qtr)

71.06%

PBYI Earnings

Earnings (TTM)

23.2M

Earnings Growth (Yr)

250.53%

Earnings Growth (Qtr)

548.6%

PBYI Profitability

Operating Margin

74.38%

EBT Margin

10.13%

Return on Equity

32.69%

Return on Assets

10.53%

Free Cashflow Yield

22.5%

PBYI Investor Care

Shares Dilution (1Y)

3.19%

Diluted EPS (TTM)

0.47

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	226.6M	219.1M	243.6M	0
2023	235.1M	230.1M	229.1M	235.6M
2022	200.7M	206.9M	217.7M	228.0M
2021	272.1M	254.9M	250.4M	253.2M
2020	224.4M	241.1M	235.5M	225.1M
2019	283.5M	286.7M	280.4M	272.3M
2018	86.3M	145.0M	201.5M	251.0M
2017	0	0	0	27.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

CEO	Mr. Alan H. Auerbach
WEBSITE	pumabiotechnology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	192

Puma Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for Puma Biotechnology Inc? What does PBYI stand for in stocks?

PBYI is the stock ticker symbol of Puma Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Puma Biotechnology Inc (PBYI)?

As of Fri Dec 20 2024, market cap of Puma Biotechnology Inc is 134.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PBYI stock?

You can check PBYI's fair value in chart for subscribers.

Is Puma Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether PBYI is over valued or under valued. Whether Puma Biotechnology Inc is cheap or expensive depends on the assumptions which impact Puma Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PBYI.

What is Puma Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, PBYI's PE ratio (Price to Earnings) is 5.81 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PBYI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Puma Biotechnology Inc's stock?

In the past 10 years, Puma Biotechnology Inc has provided -0.345 (multiply by 100 for percentage) rate of return.